Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 15/20 | 0.38 |
| ▸ | HTR2A | P28223 | 9/20 | 0.38 |
| ▸ | HTR1A | P08908 | 8/20 | 0.38 |
| ▸ | HTR7 | P34969 | 8/20 | 0.38 |
| ▸ | DRD2 | P14416 | 7/20 | 0.38 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
| ▸ | LDHA | P00338 | 2/20 | 0.34 |
| ▸ | LDHB | P07195 | 2/20 | 0.34 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3193721 | 0.89 | CHEK1 (0.41) | HTR6HTR2AHTR1AHTR7DRD2 | |
| SCHEMBL3204460 | 0.87 | ALDH1A1 (0.40) | TP53 | |
| SCHEMBL3194776 | 0.87 | CD274 (0.41) | HTR6HTR2AHTR1AHTR7DRD2 | |
| SCHEMBL3193797 | 0.84 | HRH1 (0.44) | HTR6HTR2AHTR1AHTR7DRD2 | |
| SCHEMBL9884423 | 0.84 | TP53 (0.33) | HTR6HTR2AHTR1AHTR7DRD2 | |
| SCHEMBL3207197 | 0.83 | CHEK1 (0.35) | HTR6HTR2AHTR1AHTR7DRD2 | |
| Hydrochloric Acid SCHEMBL3214789 | 0.83 | TP53 (0.33) | HTR6HTR2AHTR1AHTR7DRD2 | |
| SCHEMBL3829616 | 0.83 | RXFP1 (0.38) | — | |
| SCHEMBL3210442 | 0.82 | CHEK1 (0.40) | TP53 | |
| SCHEMBL3206896 | 0.81 | VSIR (0.39) | PDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2119703-B1 | NOVEL INDOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON I B KINASE | SANTEN PHARMACEUTICAL CO LTD (JP) | 2012-12-12 | — | — | EP | disclosed |
| US-8193237-B2 | Indole derivative having IκB kinase β inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-06-05 | — | — | US | disclosed |
| US-8193237-B2 | Indole derivative having IκB kinase β inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-06-05 | — | — | US | disclosed |
| US-8193237-B2 | Indole derivative having IκB kinase β inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-06-05 | — | — | US | disclosed |
| US-20100041628-A1 | NOVEL INDOLE DERIVATIVE HAVING IKAPPAB KINASE BETA INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041628-A1 | NOVEL INDOLE DERIVATIVE HAVING IKAPPAB KINASE BETA INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-02-18 | — | — | US | disclosed |
| EP-2119703-A1 | NOVEL INDOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON I B KINASE | Santen Pharmaceutical Co., Ltd (JP) | 2009-11-18 | — | — | EP | disclosed |
| EP-2119703-A1 | NOVEL INDOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON I B KINASE | Santen Pharmaceutical Co., Ltd (JP) | 2009-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041628-A1 | NOVEL INDOLE DERIVATIVE HAVING IKAPPAB KINASE BETA INHIBITORY ACTIVITY | NFKBIA, IKBKB, IKBKG | HTR6 2920/4885HTR2A 3001/4885HTR1A 2611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.